Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAT5906 vs Lucentis in wet AMD
NCT05439629Phase 3Completed
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- Jul 2022
- Primary completion
- Apr 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of BAT5906 in neovascular age-related macular degeneration (NVAMD), sponsored by Bio-Thera Solutions, Ltd.. Started Jul 2022; status: completed.
02
Drugs
BAT5906
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT05439629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05439629.